TLR4 and systemic sclerosis: Despite the limited number of these patients, their percentage of circulating M2 and hybrid TLR4+M2 monocytes was lower than other SSc-ILD patients not treated with nintedanib, suggesting the capability of the drug to reduce the percentage of these circulating monocytes, which might play a role in the fibrotic process of SSc-ILD.